


CLAIMS

What is claimed is:

1. Use of the hydrogenated pyrido [4,3-b] indole derivatives of the formula (I)



wherein R_1 is Me, Et or $PhCH_2$;

R_2 is H, $PhCH_2$ or 6-Me-3-Py- $(CH_2)_3$;

R_3 is H, Me or Br;

provided that

(a) when $---$ represents a single bond, then

$R_1 = R_3 = Me$; $R_2 = H$; and the compound is in the form of a cis (\pm) isomer; or

(b) when $---$ represents a double bond, then

(i) $R_1 = Et$ or $PhCH_2$, $R_2 = R_3 = H$.

(ii) $R_1 = R_3 = Me$, $R_2 = PhCH_2$.

(iii) $R_1 = Me$, $R_2 = 6-Me-3-Py-(CH_2)_3$, $R_3 = H$,

(iv) $R_1 = R_3 = Me$, $R_2 = 6-Me-3-Py-(CH_2)_3$,

(v) $R_1 = Me$, $R_2 = H$, $R_3 = H$ or Me,

(vi) $R_1 = Me$, $R_2 = H$, $R_3 = Br$,

and salts thereof with pharmacologically acceptable acids and quaternary derivatives
as the agents for the treatment of neurodegenerative diseases.